Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Guerbet
ClinicalTrials.gov Identifier:
NCT01523873
First received: January 26, 2012
Last updated: October 31, 2013
Last verified: October 2013
  Purpose

The main purpose of this study is to prospectively assess the general safety profile of Dotarem


Condition
General Safety Profile of DOTAREM®

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)

Further study details as provided by Guerbet:

Primary Outcome Measures:
  • Frequency of Adverse Events [ Time Frame: During the time of usual follow-up post Dotarem administration, with an expected average of less than 24 hours ] [ Designated as safety issue: Yes ]

Enrollment: 35921
Study Start Date: November 2008
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All consecutive patients scheduled for a Dotarem®-enhanced MRI over a one year period at each participating radiological site

Criteria

Inclusion Criteria:

  • patient scheduled for a Dotarem®-enhanced MRI

Exclusion Criteria:

  • patient with a contra-indication to MR examination
  • patient with a contra-indication to Dotarem® injection as per local SPC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01523873

Locations
France
Guerbet
Roissy CdG, France, 95943
Sponsors and Collaborators
Guerbet
  More Information

No publications provided

Responsible Party: Guerbet
ClinicalTrials.gov Identifier: NCT01523873     History of Changes
Other Study ID Numbers: DGD-55-001
Study First Received: January 26, 2012
Last Updated: October 31, 2013
Health Authority: Argentina: Ministry of Health
Argentina: Ethics Commitee
China: Ethics Committee
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
France: Conseil National de l'Ordre des Médecins
France: The Commission nationale de l’informatique et des libertés
Germany: Federal Institute for Drugs and Medical Devices
India: Institutional Review Board
Italy: Ethics Committee
Saudi Arabia: Ethics Committee
Spain: Ethics Committee
Spain: Spanish Agency of Medicines

ClinicalTrials.gov processed this record on August 28, 2014